Topotecan and Cyclophosphamide in Adults with Relapsed Sarcoma

Table 2

Treatment and disease outcome in patients treated with topotecan/cyclophosphamide.

Patient	Age at TC treatment	Diagnosis	Time to relapse (months)	Prior therapy	TTP with TC	Best response with TC	Outcome
1	51.5	RMS	11.8	VDC	1.6	PD	DOD
2	26.3	RMS	24.8	VAC, then VDC	2.0	PD	DOD
3	31.0	RMS	15	VAC, then VDC	2.3	PD	DOD
4	29.5	RMS	47.6	VDC/IE	4.3	PR	DOD
5	23.3	RMS	16	VDC/IE	1.8^*	PR	DOD
6	49.6	RMS	19	VDC/IE	2.5^*	PD	DOD
7	19.0	EWS	38	VDC/IE	1.5	PD	ANED
8	43.2	EWS	35.4	VDC/IE	5.3	PD	DOD
9	23.3	EWS	14.3	VDC/IE	2.3	PD	DOD
10	17.7	EWS	13.1	VDC/IE	6.1	SD	DOD
11	56.6	EWS	13.0	VDC/IE	13^*	SD	DOD
12	32.0	DSRCT	10.1	VDC/IE	7.0	SD	DOD
13	46.7	SS	14.4	Dox, then Gem	5.6	PR	DOD
14	24.8	SS	42.5	AI	5.6	SD	DOD
15	57.4	LMS	80.5	AI	1.8	PD	DOD

TTP, time to progression; RMS, rhabdomyosarcoma; EWS, Ewing’s sarcoma; DSRCT, desmoplastic small round cell tumour; PD, progressive disease; PR, partial response; SD, stable disease; DOD, dead of disease; ANED, alive no evidence of disease.
^*Discontinued TC for other than disease progression.